Pharsight

Oracea is owned by Galderma Labs Lp.

Oracea contains Doxycycline.

Oracea has a total of 11 drug patents out of which 5 drug patents have expired.

Expired drug patents of Oracea are:

Oracea was authorised for market use on 26 May, 2006.

Oracea is available in capsule;oral dosage forms.

Oracea can be used as treatment of only inflammatory lesions (papules and pustules) of rosacea.

The generics of Oracea are possible to be released after 19 December, 2027.

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
US8603506	August, 2015	Terminated-Denied	GALDERMA LABORATORIES, INC.	Dr. Reddy’s Laboratories, Ltd.
US8206740	June, 2013	FWD Entered
US8394406	June, 2013	FWD Entered
US8394405	June, 2013	FWD Entered	Supernus Pharmaceuticals, Inc.	Amneal Pharamceuticals, LLC

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8603506	GALDERMA LABS LP	Methods of treating acne	Apr, 2022 (11 months ago)
US7211267	GALDERMA LABS LP	Methods of treating acne	Apr, 2022 (11 months ago)
US9241946	GALDERMA LABS LP	Methods of treating acne	Apr, 2022 (11 months ago)
US10058564	GALDERMA LABS LP	Methods of treating acne	Apr, 2022 (11 months ago)
US7232572	GALDERMA LABS LP	Methods of treating rosacea	Apr, 2022 (11 months ago)
US8709478	GALDERMA LABS LP	Once daily formulations of tetracyclines	Apr, 2024 (1 year, 18 days from now)
US8394406	GALDERMA LABS LP	Once daily formulations of tetracyclines	Apr, 2024 (1 year, 18 days from now)
US8394405	GALDERMA LABS LP	Once daily formulations of tetracyclines	Apr, 2024 (1 year, 18 days from now)
US8470364	GALDERMA LABS LP	Once daily formulations of tetracyclines	Apr, 2024 (1 year, 18 days from now)
US8206740	GALDERMA LABS LP	Once daily formulations of tetracyclines	Dec, 2025 (2 years from now)
US7749532	GALDERMA LABS LP	Once daily formulations of tetracyclines	Dec, 2027 (4 years from now)